Adenosine given in the heart artery during emergency treatment of a heart attack
Tests adenosine in adults having a ST-elevation heart attack, to prevent slow blood flow.
Plain-language title generated from the registry record
Registry title: Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
Key facts
- Where
- Karachi and Lahore, PakistanSee the 2 sites
Where in Pakistan
- Dow University of Health Sciences,KarachiKarachi, PakistanTaking people
- Punjab institute of cardiology LahoreLahore, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prof Muzaffar Ali Zahidi
- Trial code
- NCT07898696
- Record updated
- 27 October 2026
- Original description
The REFLOW AMI Trial aims to determine whether prophylactic high-dose intracoronary adenosine reduces slow-flow or no-reflow (SNR) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).Read full original descriptionShow less
Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial Infarction The REFLOW AMI Trial
The REFLOW AMI Trial aims to determine whether prophylactic high-dose intracoronary adenosine reduces slow-flow or no-reflow (SNR) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
Slow-flow or no-reflow occurs when blood flow to the heart muscle remains reduced despite treatment of the blocked coronary artery. This complication can lead to greater heart muscle damage and worse clinical outcomes.
The study will evaluate a protocol involving 200 micrograms of intracoronary adenosine administered before each balloon or stent inflation during PPCI. Researchers will compare outcomes with standard PPCI care without prophylactic adenosine.
The main questions the study aims to answer are:
* Does prophylactic intracoronary adenosine reduce the incidence of slow-flow or no-reflow after PPCI? * Does the protocol improve post-PCI coronary blood flow, assessed by TIMI flow grade and myocardial blush grade? * What are the rates of major adverse cardiovascular events (MACE) during hospitalization and at 30 days? * Does the protocol affect left ventricular ejection fraction (LVEF) at discharge and at 30 days? * Does the protocol improve functional capacity at 30 days, assessed by the six-minute walk test? * Is the prophylactic adenosine protocol safe?
Participants will undergo PPCI according to their assigned study group and will be assessed for angiographic outcomes, safety events, and clinical outcomes during hospitalization and follow-up, including at 30 days.
Inclusion: 18 years and older of either gender; Diagnosis of STEMI; Undergoing primary PCI.
Exclusion: Known hypersensitivity to adenosine; Myocardial Infarction in non - obstructive coronaries (MINOCA); Cardiogenic shock; Severe hypotension (SBP <90 mmHg); Bradycardia with HR < 50 bpm without pacemaker; Severe asthma or COPD with bronchospasm; Pregnancy; Spontaneous coronary artery dissection (SCAD); Lesions unable to be crossed with coronary wire.